Jovanović, Dragana (58721901700)Dragana (58721901700)JovanovićRoksandić-Milenković, Marina (56033494500)Marina (56033494500)Roksandić-MilenkovićKotur-Stevuljević, Jelena (6506416348)Jelena (6506416348)Kotur-StevuljevićCeriman, Vesna (57204881031)Vesna (57204881031)CerimanVukanić, Ivana (57204874768)Ivana (57204874768)VukanićSamardzić, Natalija (56033770200)Natalija (56033770200)SamardzićPopević, Spasoje (54420874900)Spasoje (54420874900)PopevićIlić, Branislav (56806538200)Branislav (56806538200)IlićGajić, Milija (57204877678)Milija (57204877678)GajićSimon, Marioara (55460227500)Marioara (55460227500)SimonSimon, Ioan (16032371100)Ioan (16032371100)SimonSpasojević-Kalimanovska, Vesna (6602511188)Vesna (6602511188)Spasojević-KalimanovskaBelić, Milica (57204881662)Milica (57204881662)BelićMirkov, Damjan (57214282798)Damjan (57214282798)MirkovŠumarac, Zorica (6603643930)Zorica (6603643930)ŠumaracMilenković, Vladislav (57204882061)Vladislav (57204882061)Milenković2025-06-122025-06-122019https://doi.org/10.2478/jomb-2018-0036https://www.scopus.com/inward/record.uri?eid=2-s2.0-85057603105&doi=10.2478%2fjomb-2018-0036&partnerID=40&md5=570712073c328c08df4a3063d47465afhttps://remedy.med.bg.ac.rs/handle/123456789/5878The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression ≥50% NSCLC-responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1+ NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points. © 2019 Dragana Jovanović, Marina Roksandić-Milenković, Jelena Kotur-Stevuljević, Vesna Ceriman, Ivana Vukanić, Natalija Samardzić, Spasoje Popević, Branislav Ilić, Milija Gajić, Marioara Simon, Ioan Simon, Vesna Spasojević-Kalimanovska, Milica Belić, Damjan Mirkov, Zorica Šumarac, Vladislav Milenković.biomarkerPD-L1 positive NSCLCserum amyloid A1sPD-L1